Beyond efficacy and effectiveness: conducting economic analyses during clinical trials. Dysphagia 2004;19(2):109-19
Date
09/24/2004Pubmed ID
15382799DOI
10.1007/s00455-003-0507-7Scopus ID
2-s2.0-3042558177 (requires institutional sign-in at Scopus site) 27 CitationsAbstract
Few studies have examined cost issues in the field of dysphagia. This study presents cost data collected during a clinical trial in speech-language pathology, demonstrating the types of cost analyses that can be conducted and highlighting obstacles and issues facing investigators who seek to conduct economic analyses in this arena. Seventy-nine patients were enrolled in the clinical trial to assess the impact of a swallowing intervention on swallowing and speech function. The patients were at least one year past treatment for head and neck cancer. No significant intervention differences were detected in these outcomes. A companion economic analysis was conducted in 37 of these patients using patient diaries and followup with identified health care providers. Analyses indicated that (1) the intervention did not significantly reduce health care expenditures; (2) indirect costs and costs of hospitalizations are both important factors to consider during a trial; and (3) health care costs of this population are high relative to the rest of the U.S. population. Attrition from the overall study population can pose a serious threat to the viability of an economic study. The article concludes with a discussion of how these issues can be addressed in future studies.
Author List
Waters TM, Logemann JA, Pauloski BR, Rademaker AW, Lazarus CL, Newman LA, Hamner AKAuthor
Barbara R. Pauloski PhD, CCC-SLP Associate Professor in the Communication Sciences & Disorders department at University of Wisconsin - MilwaukeeMESH terms used to index this publication - Major topics in bold
AdultAged
Cost-Benefit Analysis
Deglutition Disorders
Health Care Costs
Health Services
Humans
Middle Aged
Speech-Language Pathology
Treatment Outcome
